RESUMO
Objective To explore the expression of peripheral blood miRNA-134 in the patients with breast cancer and chemotherapy drug resistance mechanism.Methods A total of 98 cases of newly diagnosed breast cancer were divided into the chemotherapy sensitive group(n=68) and chemotherapy drug resistant group(n=30).The expression of miRNA-134 in peripheral blood was measured by adopting RT-PCR.miRNA-mimics and miRNA-inhibitor were transfected into epirubicin and docetaxel resistant cell lines,the cell apoptosis and expression levels of Bax and Caspase-3 protein were detected.Results The level of serum miRNA134 expression in the chemotherapy sensitive group was significantly higher than that in the chemotherapy drug resistant group (P＜0.05);the proliferation capacity of epirubicin and docetaxel resistant cell lines was significantly lower than that in the MCF-7 cells(P＜0.05).Compared with normal MCF-7 cell line,the expression level of miRNA-134 in the epirubicin and docetaxel resistant cell lines was significantly decreased(P＜0.05).The apoptosis rate in the miRNA-mimics group was significantly higher than that in the control group and miRNA-inhibitor group(P＜0.05).The expression of Bax and Caspase-3 protein in the miRNA-mimics group was significantly higher than that in the control group and miRNA-inhibitor group(P＜0.05).Conclusion MiRNA-134 may enhance the sensitivity of breast cancer ceils to chemotherapy by promoting the expression of Bax and Caspase-3.
RESUMO
Objective To summarize the clinical characteristics of children with coronary artery aneurysms (CAA) and thrombosis in Kawasaki disease (KD),in order to explore the safe and effective thrombolytic therapy and its prognosis.Methods The clinic,treatment and follow-up data of 210 patients with KD between January 2006 and December 2016 were retrospectively reviewed in the Department of Pediatrics,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology.The clinic signs and laboratory data for CAA with thrombosis were analyzed.The characteristics of CAA were monitored by tltrasound.All KD patients with thrombus received intravenous antithrombotic therapy,including urokinase,heparin,and oral Warfarin,and anti-platelet treatment.The effectiveness of antithrombotic treatment was evaluated by measuring the ability to dissolve the thrombus.Results Fourteen cases in 210 patients with KD developed CAA,and had associated thrombosis.In these 14 patients,the largest diameter of CAA was 18.5 mm,and the average value was 12.6 mm.There was no special blood analysis in CAA with thrombus.Moreover,typical KD symptoms and acute myocardial infarction were not found in CAA with thrombosis.Thrombus occurred in giant aneurysms,and 2 patients had multiple thrombosis.After thrombolytic therapy,12 cases in the 14 patients had successful thrombolysis,2 patients had thrombus organization and coronary artery stenosis.Conclusions Neither clinical features nor laboratory data could reliably predict CAA associated thrombosis.Thrombus was easily formed in giant CAA.Frequent and periodly follow-up are important to detect thrombosis in KD patients with giant coronary artery.Therapy with adequate intravenous antithrombotic therapy and anti-platelet treatment earlier can effectively dissolve thrombus in KD patients,and avoid deterioration.